Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ReoPro cuts angioplasty complications in half:

This article was originally published in Clinica

Executive Summary

Centocor's antithrombotic drug ReoPro cut heart attacks and death six months after angioplasty by 46% in the EPILOG trial (Evaluation of PTCA to Improve Long-Term Outcome by c7E3 GP IIb/IIIa Receptor Blockade). At the same time it reduced the need for emergency revascularisation by 53.7%, said chairman of the Cleveland Clinic's cardiology department Dr Eric Topol. ReoPro inactivates IIb/IIIa binding sites on the surface of blood platelets.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT089537

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel